Developments include acceptance of 12 Australian patents, issuance of 5 Canadian patents and 3 patents in the United States
Filament’s industry-leading global IP portfolio contains 46 allowed patents relating to the extraction, purification, standardization, and delivery of naturally-derived psychedelic APIs
VANCOUVER, BC, Aug. 13, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced that it has expanded its intellectual property (IP) portfolio with the acceptance of twelve patents by IP Australia for processes relating to the development of botanical psychedelic drugs. Filament has been issued a further five patents by the Canadian Intellectual Property Office (CIPO), and three patents by the United States Patent and Trademark Office (USPTO), also for methods of extraction, purification, standardization, and delivery of naturally-derived psychedelic drug candidates.
“Our intellectual property represents a unique derisking of the psychedelic business model,” said Taran Grey, Director of Intellectual Property at Filament Health. “Our patents do not protect just one of thousands of possible synthetic polymorphs, but rather the most efficient means to produce naturally-derived, complex APIs with the potential to significantly improve patient outcomes. We will continue to grow our operations globally with confidence in the security of our innovations.”
Australia is currently the only country in the world to allow authorized psychiatrists to prescribe psilocybin. Filament is actively developing its network of domestic Australian partners, and completed an export of PEX010, its botanical psilocybin drug candidate, to Reset Mind Sciences in Perth, Western Australia earlier this year – the first botanical psilocybin to be exported to Australia.
“As the premier global supplier of cGMP botanical psilocybin, the protection of Filament’s drug candidates and intellectual property is critical for the distribution of our drug products to support clinicians, patients and the continuation of psychedelic research and development around the world,” said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. “We are pleased to see that our innovative technology continues to be recognized internationally.”
Filament holds a total of 46 accepted patents from Canada, the United States, Australia and Mexico.
